Oral Proteins and Peptides Industry Outlook: Drug delivery innovation and biologics expand oral therapeutics through 2036

Industry Overview:

The global oral proteins and peptides market was valued at USD 3.94 billion in 2025 and is estimated to reach USD 4.36 billion in 2026, reflecting a growth rate of 10.7%. The oral proteins and peptides market is witnessing rapid growth driven by increasing prevalence of chronic diseases, rising demand for non-invasive therapeutic options, and advancements in protein and peptide drug formulation technologies. Growing awareness of oral delivery advantages, such as patient compliance and reduced injection dependency, fuels adoption across metabolic, gastrointestinal, and endocrine disorders. Biotechnology advancements enable stable, bioavailable oral formulations of traditionally injectable proteins. Increasing investment in R&D by pharmaceutical companies accelerates pipeline development. Expansion of healthcare infrastructure in emerging economies further supports market penetration.

Industry Insights: Scale, Segments, and Shifts

• Market Size & Growth: The global oral proteins and peptides market is projected to reach USD 13.48 billion by 2036, registering a compound annual growth rate (CAGR) of 11.9% between 2026 and 2036.

• Segment Analysis: Insulin-based oral formulations, accounting for nearly 35% of the market, maintaining leadership due to the critical role of insulin in diabetes management and growing patient preference for oral over injectable therapies. Gastrointestinal and inflammatory disease therapeutics are anticipated to witness the fastest growth due to expanding clinical pipelines and advancements in targeted oral biologic delivery technologies.

• Regional Highlights: North America accounts for approximately 44% of the global market share in 2025, supported by strong pharmaceutical innovation, high biologics adoption, advanced clinical research infrastructure, and significant investment in peptide drug development, while Asia Pacific is witnessing rapid growth driven by increasing pharmaceutical manufacturing capabilities and rising healthcare expenditure.

• Competitive Landscape: The market is moderately consolidated with leading companies including Novo Nordisk A/S, Eli Lilly and Company, Entera Bio Ltd., Chiasma Inc., Oramed Pharmaceuticals Inc., AstraZeneca PLC, Roche Holding AG, AbbVie Inc., Sanofi S.A., and Biocon Limited. Industry participants are focusing on novel oral delivery platforms, strategic licensing agreements, peptide formulation technologies, and expansion of biologics pipelines.

Factors Shaping the Next Decade

Market Gaps / Restraints: Oral protein and peptide formulations face challenges with enzymatic degradation and low absorption rates. High R&D costs and lengthy regulatory approval processes limit the number of products reaching commercialization. Stability issues under varied storage conditions constrain market expansion.

Key Trends and Innovations: Emerging trends include development of nanoparticles, mucoadhesive systems, and permeation enhancers to improve oral bioavailability. Advances in formulation chemistry are enabling larger therapeutic proteins to be delivered orally. Personalized medicine and tailored peptide therapies are gaining momentum.

Potential Opportunities: The growing diabetic population creates opportunities for oral insulin delivery solutions. Expansion into gastrointestinal and oncology peptides offers new therapeutic avenues. Collaborations between biotech startups and pharmaceutical companies can accelerate commercialization of novel formulations.

Recent Development: 

• May 2026: Novo Nordisk expanded late-stage clinical development of next-generation oral peptide therapies targeting obesity and metabolic disorders with improved bioavailability.

• March 2026: Entera Bio announced positive clinical progress for its oral peptide platform designed for endocrine and bone health indications.

• November 2025: Oramed Pharmaceuticals advanced development of its oral insulin delivery platform through expanded international clinical evaluation programs.

• October 2025: the three-year-old partnership between Bristol Myers Squibb and Massachusetts firm AI Proteins aims to leverage the latter's AI-powered platform to find and create therapeutic miniproteins for two unidentified targets.

Industry Outlook Scope: 

By Therapeutic Type

• Insulin & Anti-diabetic Peptides

• Gastrointestinal Peptides

By Delivery Technology

• Nanoparticle-based Formulations

• Mucoadhesive Systems

By Region

• North America

o U.S. 

o Canada

o Mexico

• Europe

o UK

o Italy

o Spain

o Germany

o France

o BENELUX

o Nordics

o Rest of Europe

• Asia Pacific

o China

o India

o Japan

o South Korea

o Southeast Asia

o Australia & New Zealand

• Middle East & Africa

o Saudi Arabia

o Other GCC

o South Africa

o Rest of Middle East & Africa

• South America

o Brazil

o Chile

o Argentia

o Rest of South America

Geographical Insights: Emerging Corridors of Growth

Regional Overview: Europe continues strengthening its position through robust biotechnology research, increasing peptide drug approvals, and growing investments in advanced pharmaceutical manufacturing. Asia Pacific is emerging as the fastest-growing region owing to expanding biologics production, increasing clinical trial activity, and rising prevalence of chronic metabolic disorders across China, Japan, South Korea, and India. The Middle East is witnessing improving access to innovative biologic therapies through healthcare modernization initiatives, while South America is gradually expanding adoption of advanced peptide therapeutics supported by improving healthcare infrastructure.

Countries to Watch: United States remains the global leader in oral peptide drug innovation through strong pharmaceutical research, biotechnology investment, and regulatory approvals. Denmark continues driving scientific advancement through leading peptide drug manufacturers and biologics expertise. China is rapidly expanding peptide manufacturing capabilities and clinical development supported by increasing pharmaceutical research investments. .

Regulatory Environment and Policy Support

Government Regulations & Supportive Policies: The industry operates under the United States Food and Drug Administration Biologics License Application framework, European Medicines Agency Guidelines on Biological Medicinal Products, International Council for Harmonisation Good Clinical Practice Guidelines, and Good Manufacturing Practice regulations, ensuring product safety, efficacy, manufacturing quality, and regulatory compliance for oral biologic therapies.

Key Government Initiatives: Programs including the United States Advanced Research Projects Agency for Health (ARPA-H), European Horizon Europe Programme, China Healthy China 2030, and Japan Pharmaceutical and Medical Device Development initiatives are supporting biologics innovation, peptide research, and advanced drug delivery technology development.

Competitive Landscape and Strategic Outlook

The oral proteins and peptides industry is moderately consolidated, with pharmaceutical innovators investing heavily in proprietary drug delivery platforms, biologics research, and strategic licensing partnerships. Leading companies are accelerating clinical development of oral peptide therapeutics while expanding manufacturing capabilities for complex biologic formulations. Emerging biotechnology firms are differentiating themselves through novel absorption technologies, artificial intelligence-assisted drug discovery, and targeted oral delivery systems designed to overcome long-standing bioavailability challenges.

Industry Competition: 

• Novo Nordisk

• Eli Lilly and Company

• Pfizer Inc.

• Sanofi S.A.

• Roche Holding AG

• AstraZeneca PLC

• Amgen Inc.

• GlaxoSmithKline plc

• Boehringer Ingelheim

• Mitsubishi Tanabe Pharma

• Helsinn Group

• Intas Pharmaceuticals

Analyst Perspective

Analysts anticipate sustained growth driven by rising chronic disease prevalence, technological advances in oral delivery, and patient preference for non-invasive options. Commercialization of oral insulin and other therapeutic peptides will be a significant revenue driver. Innovation in bioavailability and formulation stability will determine competitive positioning. Emerging markets are expected to gain importance with improving healthcare access. Strategic collaborations and licensing deals will accelerate time-to-market. Long-term success hinges on regulatory compliance, technological differentiation, and cost-effective production.

What to Expect from Outlook:

1. Save time carrying out entry-level research by identifying the size, growth trends, major segments, and leading companies in the Global Oral proteins and peptides Market

2. Use PORTER’s Five Forces analysis to assess the competitive intensity and overall attractiveness of the Global Oral proteins and peptides Market sector.

3. Profiles of leading companies provide insights into key players’ regional operations, strategies, financial results, and recent initiatives.

4. Add weight to presentations and pitches by understanding the future growth prospects of the Global Oral proteins and peptides Market with a forecast for the decade by both market share (%) & revenue (USD Billion). 

Frequently Asked Questions (FAQs)

Q1. What is the current size of the global oral proteins and peptides industry?

Answer: The global oral proteins and peptides industry was valued at USD 3.94 billion in 2025.

Q2. What is the projected market value of the oral proteins and peptides industry by 2036?

Answer: The market is projected to reach USD 13.48 billion by 2036, growing at a CAGR of 11.9% during 2026–2036.

Q3. What are the key factors driving the growth of the oral proteins and peptides industry?

Answer: Growth is driven by advancements in oral drug delivery technologies, increasing prevalence of chronic diseases, expanding biologics pipelines, growing demand for non-invasive therapies, and rising pharmaceutical investment in peptide-based therapeutics.

Q4. Which application segment holds the largest share of the oral proteins and peptides industry?

Answer: Metabolic disorder therapeutics account for approximately 42% of the market owing to increasing adoption of oral glucagon-like peptide-1 receptor agonists and oral diabetes therapies.

Q5. What are the major trends shaping the oral proteins and peptides industry?

Answer: Key trends include nanoparticle drug delivery, permeation enhancers, lipid-based formulations, enteric-coated delivery systems, artificial intelligence-assisted peptide design, and advanced oral biologic delivery technologies.

Q6. Which region dominates the global oral proteins and peptides industry?

Answer: North America dominates the market with approximately 44% share in 2025, supported by strong biotechnology innovation, pharmaceutical research, and widespread biologics adoption.

Q7. Which countries are expected to be key growth markets for oral proteins and peptides?

Answer: The United States, Denmark, and China are expected to be major growth markets due to advanced biologics research, pharmaceutical innovation, expanding clinical development, and increasing investment in oral peptide drug delivery technologies.